NASA and Roscosmos Chiefs Meet in Florida to Discuss Moon and ISS Cooperation 
Dollar Holds Steady as Markets Shift Focus to 2026 Rate Cut Expectations 
NASA Astronauts Wilmore and Williams Recover After Boeing Starliner Delay 
Astronomers have discovered another puzzling interstellar object − this third one is big, bright and fast 
Europe Confronts Rising Competitive Pressure as China Accelerates Export-Led Growth 
Kennedy Sets September Deadline to Uncover Autism Causes Amid Controversy 
RBI Cuts Repo Rate to 5.25% as Inflation Cools and Growth Outlook Strengthens 
Asian Markets Mixed as Fed Rate Cut Bets Grow and Japan’s Nikkei Leads Gains 
FDA Pilot Program Eases Rules for Nicotine Pouch Makers 
Asia’s IPO Market Set for Strong Growth as China and India Drive Investor Diversification 
Citi Sets Bullish 2026 Target for STOXX 600 as Fiscal Support and Monetary Easing Boost Outlook 
Lab-grown meat: you may find it icky, but it could drive forward medical research 
Neuralink Expands Brain Implant Trials with 12 Global Patients 
Gold Prices Steady as Markets Await Key U.S. Data and Expected Fed Rate Cut 
Blue Origin’s New Glenn Achieves Breakthrough Success With First NASA Mission 
Keio University researchers have successfully transplanted into a patient with a severe spinal cord injury two million neural progenitor cells derived from other people’s iPS cells as part of a clinical study, offering hope for the paralyzed.
The patient is doing well.
Over the next year, while the patient undergoes rehabilitation, the team of doctors will see how safe and effective the treatment is.
The treatment is designed for patients with “complete paralysis” who are within two to four weeks of sustaining a spinal cord injury, called the subacute phase.
The iPS cells used were stockpiled by Kyoto University’s Center for iPS Cell Research and Application.
While rehabilitation is currently the only effective treatment for a spinal cord injury, the team believes that the transplanted cells could repair damaged neural circuits and create new tissue that can transmit signals from the brain.
The team plans to do the transplant into four more patients with spinal cord injuries.
While Japan’s Ministry of Health, Labor, and Welfare approved this clinical trial in February 2019, the process of finding suitable patients was postponed due to the COVID-19 pandemic.
